NO20042779L - Partiell 5HT4-agonistholdige farmsaoytiske sammensetninger - Google Patents

Partiell 5HT4-agonistholdige farmsaoytiske sammensetninger

Info

Publication number
NO20042779L
NO20042779L NO20042779A NO20042779A NO20042779L NO 20042779 L NO20042779 L NO 20042779L NO 20042779 A NO20042779 A NO 20042779A NO 20042779 A NO20042779 A NO 20042779A NO 20042779 L NO20042779 L NO 20042779L
Authority
NO
Norway
Prior art keywords
agonist
partial
pharmaceutical compositions
containing pharmaceutical
compositions
Prior art date
Application number
NO20042779A
Other languages
English (en)
Norwegian (no)
Inventor
Jerome Aubert
Vitzing Christian
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20042779L publication Critical patent/NO20042779L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20042779A 2001-12-21 2004-07-01 Partiell 5HT4-agonistholdige farmsaoytiske sammensetninger NO20042779L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01403339A EP1321142A1 (en) 2001-12-21 2001-12-21 Solid pharmaceutical composition for oral administration of Tegaserod
PCT/EP2002/014674 WO2003053432A1 (en) 2001-12-21 2002-12-20 5ht4 partial agonist pharmaceutical compositions

Publications (1)

Publication Number Publication Date
NO20042779L true NO20042779L (no) 2004-09-17

Family

ID=8183045

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042779A NO20042779L (no) 2001-12-21 2004-07-01 Partiell 5HT4-agonistholdige farmsaoytiske sammensetninger

Country Status (31)

Country Link
US (2) US20050106236A1 (es)
EP (2) EP1321142A1 (es)
JP (1) JP4718776B2 (es)
KR (1) KR100980144B1 (es)
CN (1) CN100464749C (es)
AR (1) AR037937A1 (es)
AT (1) ATE320807T1 (es)
AU (1) AU2002361198B2 (es)
BR (1) BR0215148A (es)
CA (1) CA2470668C (es)
CO (1) CO5640102A2 (es)
CY (1) CY1105559T1 (es)
DE (1) DE60210139T2 (es)
DK (1) DK1458377T3 (es)
EC (1) ECSP105163A (es)
EG (1) EG24194A (es)
ES (1) ES2258171T3 (es)
HU (1) HU226589B1 (es)
IL (2) IL162451A0 (es)
MX (1) MXPA04006157A (es)
MY (1) MY139546A (es)
NO (1) NO20042779L (es)
NZ (1) NZ533585A (es)
PE (1) PE20030872A1 (es)
PL (1) PL369509A1 (es)
PT (1) PT1458377E (es)
RU (1) RU2322978C2 (es)
SI (1) SI1458377T1 (es)
TW (1) TWI260221B (es)
WO (1) WO2003053432A1 (es)
ZA (1) ZA200404467B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ509832A (en) * 1998-08-21 2003-11-28 Novartis Ag New oral formulation for 5-HT4 agonists or antagonists
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
MXPA05008097A (es) 2003-01-28 2006-02-08 Microbia Inc Metodos y composiciones para el tratamiento de desordenes gastrointestinales.
US20050119328A1 (en) * 2003-03-25 2005-06-02 Hetero Drugs Limited Novel crysalline forms of tegaserod maleate
EP1629280A2 (en) * 2003-05-21 2006-03-01 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4)
TW200510302A (en) * 2003-07-24 2005-03-16 Novartis Ag Stable modifications of tegaserod hydrogen maleate
ES2401769T5 (es) 2003-09-12 2020-07-01 Amgen Inc Formulación de disolución rápida de cinacalcet HCl
EP1594493A2 (en) * 2003-12-16 2005-11-16 Teva Pharmaceutical Industries Ltd. Polymorphic forms of tegaserod base and salts thereof
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
US20070259052A1 (en) 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
WO2010078449A2 (en) 2008-12-31 2010-07-08 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
JP6392754B2 (ja) 2012-08-21 2018-09-19 アーデリクス,インコーポレーテッド 体液貯留又は塩過負荷に関係する疾患及び消化管疾患の治療におけるnhe仲介の逆輸送を阻害するための化合物並びに方法
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
BR112015025805A2 (pt) 2013-04-12 2017-07-25 Ardelyx Inc compostos de ligação de nh3 e métodos para inibir o transporte de fosfato
CN104922083B (zh) * 2015-04-15 2017-12-22 湖南尔康湘药制药有限公司 磺胺嘧啶片及其制备方法
WO2017064538A1 (en) * 2015-10-16 2017-04-20 Nobel Ilac Sanayii Ve Ticaret A.S. Pharmaceutical compositions of nilotinib hydrochloride
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта
CN110267944B (zh) 2017-01-09 2024-03-08 阿德利克斯股份有限公司 可用于治疗胃肠道病症的化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0820586A (ja) * 1994-07-05 1996-01-23 Sanwa Kagaku Kenkyusho Co Ltd 1−アザビシクロ[3.3.0]オクタン誘導体、その塩及び製法並びに用途
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
NZ509832A (en) * 1998-08-21 2003-11-28 Novartis Ag New oral formulation for 5-HT4 agonists or antagonists
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
WO2000057857A1 (en) * 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration
KR100738861B1 (ko) * 1999-08-03 2007-07-16 릴리 아이코스 엘엘씨 베타-카르볼린 약학 조성물

Also Published As

Publication number Publication date
IL162451A0 (en) 2005-11-20
PL369509A1 (en) 2005-04-18
PT1458377E (pt) 2006-07-31
MXPA04006157A (es) 2004-10-27
CN1606438A (zh) 2005-04-13
EP1458377B1 (en) 2006-03-22
US20090104263A1 (en) 2009-04-23
IL162451A (en) 2009-02-11
NZ533585A (en) 2006-04-28
PE20030872A1 (es) 2003-11-24
TW200410684A (en) 2004-07-01
KR100980144B1 (ko) 2010-09-03
ECSP105163A (es) 2010-07-30
EP1321142A1 (en) 2003-06-25
MY139546A (en) 2009-10-30
US20050106236A1 (en) 2005-05-19
CO5640102A2 (es) 2006-05-31
TWI260221B (en) 2006-08-21
ATE320807T1 (de) 2006-04-15
ES2258171T3 (es) 2006-08-16
AR037937A1 (es) 2004-12-22
DE60210139T2 (de) 2006-08-17
CN100464749C (zh) 2009-03-04
JP4718776B2 (ja) 2011-07-06
RU2004122631A (ru) 2005-08-10
AU2002361198A1 (en) 2003-07-09
AU2002361198B2 (en) 2006-06-08
ZA200404467B (en) 2006-05-31
CY1105559T1 (el) 2010-07-28
BR0215148A (pt) 2004-10-19
RU2322978C2 (ru) 2008-04-27
EP1458377A1 (en) 2004-09-22
EG24194A (en) 2008-10-14
KR20040066922A (ko) 2004-07-27
DE60210139D1 (de) 2006-05-11
CA2470668A1 (en) 2003-07-03
WO2003053432A1 (en) 2003-07-03
DK1458377T3 (da) 2006-06-12
CA2470668C (en) 2011-07-05
HUP0402492A3 (en) 2008-04-28
SI1458377T1 (sl) 2006-08-31
HU226589B1 (en) 2009-04-28
HUP0402492A2 (hu) 2005-07-28
JP2005516946A (ja) 2005-06-09

Similar Documents

Publication Publication Date Title
NO20042779L (no) Partiell 5HT4-agonistholdige farmsaoytiske sammensetninger
FI20011478A (fi) Farmaseuttinen koostumus
FI20105657A (fi) Farmaseuttisia koostumuksia
FI20010780A0 (fi) Parannetut koostumukset
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
ITMI20010748A0 (it) Composizioni farmaceutiche
EE200300416A (et) Ravimvorm
BR0210619A (pt) composição
IS7051A (is) Lyfjasamsetningar
IS7081A (is) Lyfjablanda
NO20026123L (no) Farmasöytiske sammensetninger
FI20022128A (fi) Farmaseuttinen koostumus
NO20031095L (no) Farmasoytiske sammensetninger
HK1068277A1 (en) Pharmaceutical compositions comprising chelidonineor derivatives thereof
ITTO20020744A0 (it) Composizione
EE200300465A (et) Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid
FI20012242A0 (fi) Uudet farmaseuttiset yhdisteet
DE60140529D1 (de) Feuerlöschende Zusammensetzung
ITTO20020745A0 (it) Composizione
EE200200689A (et) Ravimkoostised
NO20015694L (no) Emballasje
FI5468U1 (fi) Farmaseuttinen koostumus
SE0100847D0 (sv) Novel pharmaceutical composition
SE0103116D0 (sv) Pharmaceutical combination
FIU20010427U0 (fi) Jippopakkaus

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application